Oncology Intelligence Hub
The Oncology Intelligence Hub is an operating part of CS Cancer Solutions' public-source oncology research platform. It organizes publicly available evidence — outcomes, therapies, biomarkers, clinical trials, institutional research activity, and emerging scientific discoveries — into six structured domains that make complex research context easier to find and assess.
See a live module example: Ocular (Uveal) Melanoma evidence summariesFramework
Intelligence Domains
Six interconnected domains that structure how oncology evidence is organized, contextualized, and made accessible across the platform.
Outcomes Intelligence
Examine published survival trends, treatment effectiveness patterns, recurrence measures, and evolving outcome data across cancer types and therapeutic approaches.
Explore DomainResearch Landscape Intelligence
Explore research activity, publication growth, emerging scientific priorities, and evolving evidence ecosystems across oncology.
Explore DomainClinical Trial Intelligence
Monitor active clinical trial activity, therapeutic development trends, and areas of emerging treatment investigation.
Explore DomainBiomarker Intelligence
Track biomarker prevalence, emerging molecular targets, precision oncology developments, and evolving therapeutic relevance.
Explore DomainRare Cancer Intelligence
Highlight underrepresented cancers, research gaps, emerging evidence ecosystems, and opportunities for increased scientific visibility.
Explore DomainInstitutional Intelligence
Examine oncology research activity, specialization areas, scientific contributions, and evidence-generation patterns across institutions.
Explore DomainResearch Inquiry
Questions Intelligence Can Help Explore
Structured oncology intelligence is designed to support inquiry across some of the most pressing questions in cancer research.
How are survival trends evolving across cancer types?
Which therapies are associated with improving published outcomes?
Where is clinical trial activity accelerating?
Which biomarkers are receiving increasing scientific attention?
Which rare cancers remain underrepresented in research?
Which institutions are contributing to emerging areas of oncology research?
Where are evidence gaps limiting progress and visibility?
How are oncology research ecosystems evolving globally?
